InvestorsHub Logo
Followers 10
Posts 1111
Boards Moderated 0
Alias Born 04/07/2013

Re: Whalatane post# 54557

Sunday, 07/26/2015 9:35:21 PM

Sunday, July 26, 2015 9:35:21 PM

Post# of 425701
As the old erratic poster, I have some comments to make.
I hear an excitement among Academic Cardiologists
re PCSK9 that I haven't heard since Statins entered
the therapeutic arena for reducing MI's and Strokes.
The reported connection to loss of short term memory
issues are not very different from some of the old articles incriminating Statins for the very same problem. And yet there are 40M patients taking Statins. The issue of HMO's prescribing
PCSK9 drugs to the very patients who need them most, is in
reality a financial issue and not necessarily an issue with
an unproven drug. HMO's like Kaiser are well known for throwing Quarters around as if they were Manhole Covers. As for sour grapes, that lowering Trigs are not considered a non statin
lipid lowering agent is a fact according to the AHA/ACC's new
guidelines. Since lowering LDL is the only lipid metric
accepted for approval by FDA, prior to Outcomes Trials
results, bears weight. Unfortunately if Trigs were an
accepted metric, we all would be thrilled and wealthy,
as Anchor would have been approved and AMRN stock would
be exponentially higher. The "King" and self proclaimed
Maven on Lipidology is as usual his sarcastic, insulting
boorish self. As for his lapdog cheering him on, I have one
comment. You are probably a nice guy, and IMO I would hope
that the PCSK9's are prescribed for you. You are the classic patient they are best suited for.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News